Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess the Effectiveness and Safety of Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

NCT04296162 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04296162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04296162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess the Effectiveness and Safety of Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Completed
Start date
March 10, 2020
Completion date
April 25, 2026
Enrollment
182 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer